Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

03.12.24	MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or Metastatic NSCLC (RTTNews)
25.11.24	Merck Reports Positive Topline Results From The Phase 3 ZENITH Study Evaluating WINREVAIR In PAH (RTTNews)
22.11.24	Merck Announces Approval For WELIREG In China - Quick Facts (RTTNews)
19.11.24	Merck's Phase 3 Study Of Subcutaneous Keytruda To Treat NSCLC Meets Primary Goals (RTTNews)
14.11.24	Merck Expands Oncology Pipeline By Securing License For LaNova Medicines' LM-299 (RTTNews)
12.11.24	AstraZeneca: Koselugo Phase III Trial Meets Primary Goal In Adults With Neurofibromatosis Type 1 (RTTNews)
31.10.24	Merck Cuts FY24 Earnings View, Narrows Sales Forecast After Weak Q3 Earnings - Update (RTTNews)
31.10.24	Merck & Co Inc. Q3 Profit Falls (RTTNews)
24.10.24	Merck : CDC Recommends CAPVAXIVE For Pneumococcal Vaccination In Adults 50 And Older (RTTNews)
20.10.24	Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment (RTTNews)
18.10.24	Merck's Clesrovimab Lowers RSV Disease And Hospitalization In Preterm And Full-term Infants (RTTNews)
14.10.24	Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG (RTTNews)
25.09.24	Merck Says Phase 3 KEYFORM-007 Study Did Not Meet Primary Goal Of Overall Survival (RTTNews)
25.09.24	Merck Reports Approval In Japan For KEYTRUDA Regimen For Certain Patients With NSCLC (RTTNews)
24.09.24	Merck Announces Expansion Of Nobivac NXT Platform For Treatment Of Feline Leukemia Virus (RTTNews)
18.09.24	Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults (RTTNews)
17.09.24	Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study (RTTNews)
15.09.24	Merck : KEYTRUDA Combination Cuts Death Risk By 34% In Late-Stage Breast Cancer Trial (RTTNews)
12.09.24	Health Canada Approves Merck's Keytruda As A Monotherapy To Treat MSI-H Or DMMR Solid Tumours (RTTNews)
08.09.24	Merck & Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promising Results In Phase 2 Lung Cancer Trial (RTTNews)
05.09.24	Merck's Winrevair Approved For Pulmonary Arterial Hypertension In Canada (RTTNews)
02.09.24	Biotech Stocks Facing FDA Decision In September 2024 (RTTNews)
01.09.24	Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies (RTTNews)
31.08.24	IO Biotech's Phase 3 Trial Data Fails To Show Superiority In ORR For IO102-IO103 With KEYTRUDA (RTTNews)
28.08.24	Astellas : EC Approves PADCEV Combination For First-Line Treatment Of Advanced Urothelial Cancer (RTTNews)
26.08.24	Merck's Winrevair Gets Approval In Pulmonary Arterial Hypertension In Europe (RTTNews)
22.08.24	Health Canada Approves Keytruda-Padcev Combo For Certain Patients With Urothelial Cancer (RTTNews)
11.08.24	Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray (RTTNews)
09.08.24	Merck To Buy Investigational B-Cell Depletion Therapy CN201 From Curon Biopharma For Initial $700 Mn (RTTNews)
08.08.24	Merck Discontinues Phase 3 KeyVibe-008 Study In Extensive-stage Small Cell Lung Cancer (RTTNews)
06.08.24	Daiichi Sankyo, Merck Expand Partnership To Include Merck's MK-6070 (RTTNews)
30.07.24	Merck Q2 Results Top Estimates, But Slashes FY24 Earnings Outlook (RTTNews)
30.07.24	Merck Q2 Results Beat Estimates; Cuts FY24 Adj. EPS View, Lifts Sales Forecast (RTTNews)
26.07.24	Merck Gets Positive CHMP Opinion For Keytruda Plus Padcev To Treat Urothelial Carcinoma (RTTNews)
23.07.24	Merck's Phase 2b/3 Study Of Clesrovimab To Protect Infants From RSV Disease Meets Primary Goals. (RTTNews)
12.07.24	Immutep's Eftilagimod Alfa Combination Shows Positive Phase IIb Results In Head & Neck Cancer Trial (RTTNews)
01.07.24	Orion Stock Up On FY24 Outlook Upgrade After Opevesostat Deal With Merck (RTTNews)
28.06.24	Merck: CHMP Recommends Approval Of WINREVAIR In Pulmonary Arterial Hypertension - Quick Facts (RTTNews)
27.06.24	Merck : FDA Issues Complete Response Letter For Patritumab Deruxtecan In EGFR-Mutated NSCLC (RTTNews)
26.06.24	Merck : USDA Approves NOBIVAC NXT, First RNA-Particle Vaccine For Canine Flu H3N2 (RTTNews)
18.06.24	Ligand Says Merck Receives FDA Approval For CAPVAXIVE For Adults (RTTNews)
03.06.24	Merck Says MRNA-4157-Keytruda Combination Data Shows Improvement In High-Risk Melanoma Patients (RTTNews)
03.06.24	Immutep Collaborates With Merck To Evaluate Efti In Combination Therapy For Metastatic NSCLC (RTTNews)
01.06.24	Lilly Announces Updated Data From Phase 1/2 Study Of Olomorasib In Advanced Solid Tumors (RTTNews)
30.05.24	Biotech Stocks Facing FDA Decision In June 2024 (RTTNews)
29.05.24	Merck To Acquire EyeBio; Deal Valued Up To $3 Bln (RTTNews)
29.05.24	Merck Nears $1.3 Bln Cash Deal To Buy EyeBio, With Potential $1.7 Bln In Milestone Payments : Report (RTTNews)
28.05.24	Merck Reports Positive Phase 3 KEYTRUDA Plus Chemotherapy Trial Results In TNBC Patients (RTTNews)
13.05.24	Merck Discontinues Vibostolimab And Pembrolizumab Coformulation Arm Of Phase 3 Trial In Melanoma (RTTNews)
09.05.24	Merck's Phase 3 Trial Of KEYTRUDA Plus Chemotherapy In Endometrial Cancer Fails To Meet Primary Goal (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

22:34		Dow Jones-Handel aktuell: Dow Jones verbucht letztendlich Verluste
20:03		Schwache Performance in New York: Dow Jones gibt nachmittags nach
18:01		Gewinne in New York: Dow Jones verbucht am Mittwochmittag Zuschläge
17:58		Börse London: FTSE 100 zum Ende des Mittwochshandels mit positivem Vorzeichen
17:58		Starker Wochentag in Europa: STOXX 50 klettert zum Handelsende

22:34

Dow Jones-Handel aktuell: Dow Jones verbucht letztendlich Verluste

20:03

Schwache Performance in New York: Dow Jones gibt nachmittags nach

18:01

Gewinne in New York: Dow Jones verbucht am Mittwochmittag Zuschläge

17:58

Börse London: FTSE 100 zum Ende des Mittwochshandels mit positivem Vorzeichen

17:58

Starker Wochentag in Europa: STOXX 50 klettert zum Handelsende

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Merck Co.

Aktien Top/Flop

Merck Peer Group Nachrichten

Meistgelesene Nachrichten